|
|
 | | | |
- close
- close
- close
- close
Idenix Pharmaceuticals (IDIX) |
QUOTE AND NEWS
Globe Newswire
May 2
Comment
CAMBRIDGE, Mass., May 2, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial
Globe Newswire
Apr 30
Comment
CAMBRIDGE, Mass., April 30, 2012 (GLOBE NEWSWIRE) -- Idenix Pharmaceuticals, Inc., (Nasdaq:IDIX) announced today that Idenix management will present a corporate overview at the Deutsche Bank 37th Annual Healthcare Conference on May 7, 2012 at 3:30
MarketWatch
Apr 19
Comment
Hepatitis C specialists Gilead, Idenix and Achillion were back in play Thursday, as investors reacted to positive data on Gilead’s experimental drug GS-7977.
StreetInsider.com
Apr 19
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Achillion+%28ACHN%29+Shares+Slammed%2C+Gilead+%28GILD%29%2C+Idenix+%28IDIX%29+Rip+on+New+HCV+Treatment+Data/7357166.html for the full story.
StreetInsider.com
Apr 19
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Idenix+Pharma+%28IDIX%29+Rips%2C+Reports+Encouraging+Data+from+IDX719+Phase+I/7357034.html for the full story.
Globe Newswire
Apr 19
Comment
IDX719 Demonstrates Pan-Genotypic Activity at Single Doses in HCV-Infected Patients Achieving Greater Than 3 log10 Viral Load Reductions in the 100 mg Dose Group Across Genotypes 1, 2 and 3; Three-Day Proof-of-Concept Study Underway IDX184/PegIFN/RBV
Benzinga
Apr 18
Comment
Shares of Idenix Pharmaceuticals Inc (NASDAQ: IDIX) are higher on the session by 4.31%, currently trading at $7.75
Option volatilities are higher with April +40.7 points, May +11.3 points, and July unchanged. The strike seeing the heaviest...
TheStreet.com
Apr 4
Comment
Updated with new information, including comments from the CEO of Idenix Pharmaceuticals.
BOSTON (TheStreet) -- The European Association for the Study of the Liver (EASL) finally released hepatitis C drug research abstracts Wednesday ahead of...
Marketwire
Mar 28
Comment
NEW YORK, NY -- (Marketwire) -- 03/28/12 -- Biotechnology stocks have been on an impressive run this year as favorable legislation out of Washington is allowing biotech companies of all sizes to more easily navigate regulations. Five Star Equities
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| |||||||
